Меню
Набор скоро начнётся NCT07718893

CITE: Clinical Inference Tethered to Evidence - a Retrieve-and-verify Layer for AI Care Plans

Без фазы С лечением Quality of Health Care Patient Safety Clinical Decision Support

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: CITE evidence-grounding retrieve-and-verify layer, AI care plan with safety guardrails.
Кому может быть актуально
Состояния в реестре: Quality of Health Care, Patient Safety, Clinical Decision Support. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Randomized Controlled Trial of CITE (Clinical Inference Tethered to Evidence), an Evidence-Grounding Retrieve-and-Verify Layer That Flags Unsupported and Inappropriate Recommendations in AI-Generated Care Plans, Versus AI With Safety Guardrails Alone and Unassisted Care, in Medicaid Primary Care

Обзор

This trial evaluates CITE, a retrieve-and-verify layer that audits an AI-generated care plan against a full-text evidence corpus and flags patient-specific codifiable safety hazards to the clinician. The co-primary outcomes are how accurately CITE flags these hazards (sensitivity and specificity versus blinded clinician adjudication) and its clinician alert burden and acceptance, compared with AI care plans using safety guardrails alone and with unassisted clinician care, in Medicaid primary care.

Подробное описание

Patients are randomized 1:1:1 to (1) unassisted clinician care; (2) AI-generated care plan with safety guardrails; (3) AI-generated care plan with safety guardrails plus CITE. CITE audits the finalized plan against a frozen, versioned evidence corpus and returns physician-facing flags for patient-specific codifiable safety hazards (a recommended drug contraindicated by this patient's diagnosis or laboratory value; a drug-allergy conflict; a dropped high-risk medication; a guideline-indicated therapy omitted for an active diagnosis; a stated quantity refuted by the corpus), each with a verbatim quote and citation; the clinician retains decision authority. Randomization uses a deterministic HMAC permuted-block scheme; outcome assessors are blinded to arm. The co-primary outcomes are (1) the diagnostic accuracy (sensitivity and specificity) of CITE against blinded clinician adjudication, and (2) clinician alert burden (flags per encounter) and acceptance, comparing the CITE arm with the guardrail arm; both are estimable at the enrolled sample size because they do not depend on a rare between-arm event. The unresolved codifiable-hazard rate by arm is reported as a descriptive secondary: codifiable hazards are infrequent, so the trial is not powered for a between-arm efficacy contrast on hazard reduction. A prior trial of a different mechanism (a generic deterministic rule-corpus that surfaced roughly 30 or more flags per encounter and was uninformative) was completed with null results and is registered separately; this trial evaluates a materially different, patient-specific intervention and set of outcomes. Determined exempt by WCG IRB (low risk). Analysis is pre-registered on OSF (https://doi.org/10.17605/OSF.IO/ENXCW).

Вмешательства

  • Другое CITE evidence-grounding retrieve-and-verify layer
    Reads the AI care-plan text and verifies each recommendation/claim against a full-text evidence corpus; returns physician-facing flags (commission/confabulation/unsupported/omission) with verbatim quotes and citations. Clinician retains decision authority.
  • Другое AI care plan with safety guardrails
    AI-generated care plan produced under a safety-guardrail system prompt.

Первичные конечные точки

  • Diagnostic accuracy of CITE against clinician adjudication [Срок оценки: Day 1 (index primary care encounter)]
  • Clinician alert burden (flags surfaced per encounter) [Срок оценки: Day 1 (index primary care encounter)]
Вторичные конечные точки (6)
  • Clinician action on CITE flags [Срок оценки: Day 1 (index primary care encounter)]
  • Unresolved codifiable safety-hazard rate by arm (descriptive) [Срок оценки: Day 1 (index primary care encounter)]
  • Correction of codifiable hazards within 30 days [Срок оценки: Up to 30 days after the index encounter]
  • Completed referrals within 30 days [Срок оценки: Up to 30 days after the index encounter]
  • Clinical safety composite (exploratory) [Срок оценки: Day 1 (index primary care encounter)]
  • 30-day acute care utilization (exploratory) [Срок оценки: Up to 30 days after the index encounter]

Критерии участия

Критерии включения

  • Age 18 years or older.
  • Medicaid-enrolled and attributed to a participating Waymark primary care site.
  • Primary care encounter that requires clinical reasoning (not administrative-only).
  • English-language clinical documentation.

Критерии исключения

  • Age less than 18 years.
  • Hospice or palliative-care-exclusive care plan.
  • Administrative-only or pharmacy-only encounter that does not surface a clinical decision to the supervising clinician.
  • Encounter where the supervising clinician is the principal investigator.
  • Enrollment in a competing AI-safety study within the prior 90 days.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Организация здравоохранения

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07718893 · CITE-2026-02

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗